ライフサイエンスコーパス: responder

1 n be distinguished into "responder" and "non-responder".

2 acytidine (40 patients; 15 nonresponders, 25 responders).

3 ination with concomitant ITP therapy (70% of responders).

4 rom SCI rats without TTA-P2-induced CPP (non-responders).

5 s with clinical benefit, but only in one non-responder.

6 n antipsychotic treatment responders and non-responders.

7 n and unique functional states of B cells in responders.

8 vealed variations between responders and non-responders.

9 ctivity, which were reversed in part in UDCA responders.

10 ome are different between responders and non-responders.

11 in the hearts of nonresponders compared with responders.

12 in hippocampal neurons derived from lithium responders.

13 nces fast inactivation only in variants from responders.

14 ides when comparing low responders with high responders.

15 Pre-FMT Candida levels may identify FMT responders.

16 ycles) and 7 cycles (range, 1-10 cycles) for responders.

17 ed by anti-cytokine therapy, most notably in responders.

18 enes in the tumours of responders versus non-responders.

19 gnificantly higher in responders than in non-responders.

20 om baseline in ICS nonresponders than in ICS responders.

21 to be optimized in the cohort of short-term responders.

22 er and simultaneously pose hazards for first responders.

23 sponders, 17% early responders, and 25% slow responders.

24 ase in risk of event as compared with immune responders.

25 ell subset is significantly lower in the non-responders.

26 antly increased in responders but not in non-responders.

27 mory B cells were enriched in the tumours of responders.

28 in the MitraClip arm compared with 29 super-responders (10.2%), 46 responders (16.3%), and 208 nonre

29 ompared with 29 super-responders (10.2%), 46 responders (16.3%), and 208 nonresponders (73.5%) in the

30 as responders (52%), 12 patients as partial responders (17%), and 22 patients as nonresponders (31%)

31 9% were anatomical responders with 38% super responders, 17% early responders, and 25% slow responder

32 , there were 79 super-responders (27.2%), 55 responders (19.0%), and 156 nonresponders (53.8%) in the

33 At 12 months, there were 79 super-responders (27.2%), 55 responders (19.0%), and 156 nonre

34 The proportion of responders 30 min post-dose was 91% (one-sided 97.5% con

35 vely associated with response to CRT (25% of responders, 47% of nonresponders; odds ratio 0.3 [0.12-0

36 ates, Canada, and United Kingdom (5931 valid responders; 49.2% female; mean age, 47.4 years; range, 1

37 p, 36 of the 70 patients were categorized as responders (52%), 12 patients as partial responders (17%

38 o were attack free (37.9%-48.1% vs 7.3%) and responders (85.7%-100% vs 26.8%).

39 on (HSCT) was used as consolidation in 29/30 responders (96.7%); 20/25 (80%) had no RD before HSCT.

40 es were deep and durable, with most complete responders achieving mIDH1 mutation clearance.

41 BPVT recurred (re-BPVT) in 14 (23%) responders after a median of 23 months (IQR: 11 to 39 mo

42 ous pressure and the number of cardiac index-responders after fluid bolus were similar, the arterial

43 Non-responders after optimisation did not improve during the

44 -thalamus-striatum network decreased only in responders after two treatments and after index.

45 INE and LINE), and the type I IFN pathway in responders, all independent of disease classification.

46 Our work places GPR56 as an initial collagen responder and shear-force transducer that is essential f

47 e-to-severe adult asthma patients (N = 45:34 responders and 11 non-responders) were analysed over the

48 nt (OOE) data from emergency medical service responders and 311 service request data from the City of

49 Telecommunicators are the true first responders and a critical link in the cardiac arrest cha

50 Cardiac index responders and mean arterial pressure-responders were de

51 proteins were considered to be both collagen responders and mediators of platelet adhesion, yet the s

52 s in pre-treatment oesophageal cells between responders and non-responders and test for accelerated e

53 tiation establishes that differences between responders and non-responders are maintained, with a dec

54 Microbiota and metabolome differed between responders and non-responders prior to EEN.

55 aboratory parameters after stratification in responders and non-responders to endoscopic therapy show

56 Transcriptome variations between responders and non-responders were identified using the

57 ranscriptional variations between omalizumab responders and non-responders, but also molecular insigh

58 enzalutamide shows a distinct separation of responders and non-responders, predominantly related to

59 cer) differs between antipsychotic treatment responders and non-responders.

60 ings and further revealed variations between responders and non-responders.

61 robiota and metabolome are different between responders and non-responders.

62 and ADC(mean) significantly differed between responders and nonresponders (<0.01), whereas difference

63 and PFS were significantly different between responders and nonresponders (20.3 vs. 10.6 mo, P = 0.00

64 ences in minimum ADC and maximum SUV between responders and nonresponders and comparison of timing fo

65 Perfusion was compared between responders and nonresponders at baseline, at week 2, aft

66 CCR6(+) T cells from responders and nonresponders had distinct gene expressio

67 of 26, 92%; 95% CI: 75%, 99%) in identifying responders and nonresponders in the treated groups compa

68 ppocampal cortex, and applied separately for responders and nonresponders to ECT.

69 amine differences in pain phenotypes between responders and nonresponders to intravenous lidocaine tr

70 overall survival (OS) were compared between responders and nonresponders using Kaplan-Meier and log-

71 ced pluripotent stem cells (iPSCs) from full responders and nonresponders, from subjects with diabete

72 neuronal pentraxin 2, differed between full responders and nonresponders.

73 rdiac biopsies of a representative subset of responders and nonresponders.

74 h included CPR and defibrillation by citizen responders and random bystanders.

75 s were improved to a greater degree in super-responders and responders but not in nonresponders.

76 oesophageal cells between responders and non-responders and test for accelerated epigenetic ageing in

77 uld be present before the arrival of citizen responders and the EMS.

78 sinophil activities were up-regulated in non-responders and, more importantly, omalizumab did not sig

79 nd that GBM cells can be distinguished into "responder" and "non-responder".

80 ; fluid cleared only partly in 66% ("partial responders"); and fluid remained unchanged in 6% ("nonre

81 who responded to lithium treatment (lithium responders) and not in CA3 pyramidal hippocampal neurons

82 ponders with 38% super responders, 17% early responders, and 25% slow responders.

83 ubjects, 3 patients with BD who were lithium responders, and 3 patients with BD who were nonresponder

84 n, mobile phone technologies to summon first responders, and an enhanced role for emergency telecommu

85 managers, public officials, citizens, first responders, and other decision-makers for flood forecast

86 0.26-0.94; P = 0.0006; FDR = 0.004) only in responders, and responders showed significantly more dec

87 uals with dominant Best disease and that non-responders are candidates for alternate approaches such

88 that differences between responders and non-responders are maintained, with a decrease in SPM concen

89 At least 1 citizen responder arrived before EMS in 42.0% (n = 184) of all i

90 Among positive responders, bAb net mean fluorescence intensity (MFI) wa

91 pes that had been classified as high and low responder based on NO(-) production.

92 percentile) and low (n = 6; 10th percentile) responders based on vaccine-specific antibody responses

93 Arrival of app-dispatched citizen responders before EMS was associated with increased odds

94 ce in expression level between good and poor responders before starting treatment, allowing to predic

95 the OHCA location of app-dispatched citizen responders before the Emergency Medical Services (EMS) a

96 These bred high-responder (bHR) and bred low-responder (bLR) rats model

97 These bred high-responder (bHR) and bred low-responder (bLR) rats model temperamental extremes, exhib

98 cell frequencies significantly increased in responders but not in non-responders.

99 to a greater degree in super-responders and responders but not in nonresponders.

100 ations between omalizumab responders and non-responders, but also molecular insights for controlling

101 ne reuptake inhibitor (N = 424) we show that responders, but not non-responders, display an increase

102 cipants with plasma HIV-1-RNA <50 copies/mL (responders) by the Food and Drug Administration Snapshot

103 of the microbiome failed to reveal possible responder compared with nonresponder factors.

104 rations of interferon-gamma in plasma of low responders compared to high responders prior to vaccinat

105 n = 43) had higher proportion of sub-optimal responders compared to other categories (p < 0.001).

106 Six of 8 patients in the IVIG group were responders, compared to 2 of 9 in the placebo group (p =

107 roup, 6 of 8 patients in the IVIG group were responders, compared to zero of 6 in the placebo group.

108 The patients were categorized into responders (complete or partial response) and nonrespond

109 Responders could be identified with high specificity and

110 nalyses of individual clusters revealed that responders could maintain changes induced with omalizuma

111 59.0% of responders declared that A/I is recognized as a separate

112 mpared with MRI-PDFF nonresponders, MRI-PDFF responders demonstrated both a statistically and clinica

113 = 424) we show that responders, but not non-responders, display an increase of GPR56 mRNA in the blo

114 s in The Cancer Genome Atlas express the non-responder (ERN1, IGFBP3, IGFBP5) gene signature.

115 nvolvement in scientific societies, 41.1% of responders ever attended an EAACI Congress, 20.6% an AAA

116 me during the 1st year in 28% of eyes ("full responders"); fluid cleared only partly in 66% ("partial

117 showed good predictive power to distinguish responders from non-responders (receiver operating curve

118 l time is critical in order to differentiate responders from non-responders; however, there are curre

119 entify predictive biomarkers differentiating responders from nonresponders.

120 t of nasal cytokines that discriminated high responders (G-CSF, IFN-gamma, TNF-alpha) correlated with

121 grative model to Prioritize Potential immune respondER genes (NIPPER).

122 ic analysis categorized 22 (59%) patients as responders (grades I-III) and 15 (41%) as nonresponders

123 responders or nonresponders, and within the responder group as rebounders and non-rebounders based o

124 Expression was compared between responder groups and correlated with OCT imaging biomark

125 entially expressed (DE) between high and low responder groups at 3 and 18 hours after exposure to Esc

126 hen more vaccinees were in the high- and low-responder groups versus the middle group and when vaccin

127 differed the most between the high- and low-responder groups.

128 with 8 and 16 mg, respectively (p values for responders >85% target; p = 0.142 and p = 0.009, respect

129 9% (p < .001), and half of the patients were responders (>=35% decrease of Yale-Brown Obsessive Compu

130 Responders had a median survival of 113 days (95% CI 41-

131 Responders had higher baseline tumor perfusion than nonr

132 Fecal samples from responders had higher diversity of microbiomes before ad

133 Sertraline responders had higher functional connectivity between th

134 Super responders had increased baseline vascular endothelial g

135 ared with nonresponders, whereas venlafaxine responders had lower functional connectivity.

136 of 16 months, median duration of response in responders had not been reached.

137 Only two non-responders had PD-L1 expression >1%.

138 [10%] of ten with non-Hodgkin lymphoma; all responders had PD-L1 expression).

139 onders to endoscopic therapy showed that non-responders had significantly higher levels of CRP and lo

140 potential of this biomarker to identify non-responders has yet to be evaluated.

141 n order to differentiate responders from non-responders; however, there are currently no platforms to

142 dosing regimens were classified as VO(2)peak responders (ie, Delta >=1.32 mL O(2).kg(-1).min(-1)).

143 Most patients will be classified as complete responders if intervals less than 4 weeks are used to as

144 al genes selectively overexpressed among non-responders, IGFBP3 and IGFBP5.

145 ients per assigned treatment group using non-responder imputation.

146 etail how we believe UV-DDB may be the first responder in altering the structure of damage containing

147 (MTV)) were applied separately to categorize responders in CT and PET imaging studies.

148 to open-label ixekizumab were imputed as non-responders in logistic regression analysis.

149 collected from health care workers and first responders in New York City and the Detroit metropolitan

150 Baseline predictors of clinical super-responders in patients with HF and severe secondary MR i

151 T derived features were able to identify non-responders in regard of all endpoints (DFS p < 0.001, LC

152 rimary end point) was not different (41 v 47 responders in the BD and C-BD groups, respectively; rela

153 l killer T (iNKT) cells serve as early rapid responders in the innate immune response to self-derived

154 Among 25 primary responders in the ruxolitinib group, six had progressed

155 -protocol (PP) population, there were 90.21% responders in the TwinrabTM arm and, 94.37% in the HRIG

156 ore, at follow-up, time to peak in metabolic responders increased significantly (P = 0.019).

157 ntitative disease activity tool (the IgG4-RD Responder Index) and the validation of classification cr

158 HIV-infected immunological non-responders (INR) fail to reconstitute their CD4 + T cell

159 r prognosis is inferior to the immunological responders (IR).

160 Reliable identification of good and poor responders is important.

161 ogistic regression identified early endpoint responders/late endpoint failures as less likely to be o

162 ded reasons for failure among early endpoint responders/late endpoint failures were receipt of non-st

163 Citizen responders located 1.8 km (1.1 miles) from the OHCA were

164 logists responded, and 87.1% (825 of 946) of responders met eligibility criteria.

165 Responders' microbiomes converged toward the composition

166 dia-class bacteria, whereas after treatment, responders' microbiomes showed increased Bacteroidia and

167 Here, we classify weight loss responders (N = 106) and non-responders (N = 97) of over

168 and baseline HVPG > 16 mm Hg, only the HVPG responders (n = 32) had a good prognosis, with lower reb

169 The HVPG responders (n = 71) had lower rebleeding risk (10% vs. 3

170 ify weight loss responders (N = 106) and non-responders (N = 97) of overweight non-diabetic middle-ag

171 e patients who met the eligibility criteria (responders, n = 14, and nonresponders, n = 15) and 26 he

172 nce phase, eight patients were classified as responder (observed response rate: 44.4%; intention-to-t

173 DDP-incomplete responders with CDDP-complete responders of CC patients and CDDP-insensitive CC cell l

174 Mast cells (MCs) are the initial responders of innate immunity and their degranulation co

175 T cells, the major first responders of the immune system, are produced in the thy

176 ment are categorised in partial and complete responders one day after the treatment.

177 esponse (PBIR), which regards a patient as a responder only if they have achieved and remain in respo

178 ethod for analyzing the DOR data, which uses responders only, the above procedure includes all patien

179 e expression changed after treatment in good responders only.

180 rence standard, and patients were defined as responders or nonresponders based on the grading scale b

181 m anti-TNF-treated RA patients classified as responders or nonresponders to therapy.

182 Subjects were categorized as anatomical responders or nonresponders, and within the responder gr

183 or cingulate cortex (ACC) FC relative to non-responders (p < 0.001) which was associated with improve

184 86) compared to 15 days (95% CI 6-24) in non-responders (p = 0.002).

185 uro 10,198.59 (30 injections) per additional responder patient (3-month nonresponders and 6-month res

186 euro 7927.02 (14 injections) per additional responder patient would be needed.

187 tumor-circulating immune cell interaction in responder patients but not in those patients that progre

188 the network and identification of candidate responder patients for NOTCH-directed therapies.

189 s from an unbiased cohort of 111 exceptional responder patients using multiple platforms to profile g

190 Candidate GSi-responder patients were characterized by distinct transc

191 imulated BD CA3 neurons derived from lithium responder patients were hyperexcitable.

192 During treatment, these responder patients, as well as hematopoietic cells treat

193 nal aflibercept, ranibizumab and bevacizumab responder patients, respectively.

194 9% of cancer types to harbor prospective GSi-responder patients, which was adapted into a 20-gene GSi

195 By RNASeq analysis we found that the non-responder phenotype is significantly linked with the exp

196 iched among the over-expressed genes by high responder phenotype.

197 rentially regulated between the high and low responder phenotypes.

198 In addition, low responder pigs with high plasma interferon-gamma showed

199 wed lower (p < 0.01) birth weights than high responder pigs.

200 a distinct separation of responders and non-responders, predominantly related to status of wild-type

201 tabolome differed between responders and non-responders prior to EEN.

202 mycobiota-focused approaches to identify FMT responders prior to therapy initiation.

203 in plasma of low responders compared to high responders prior to vaccination.

204 response was 4.1 months with ten (71%) of 14 responders proceeding to a subsequent allogeneic stem-ce

205 ne <50%), and 25 patients were classified as responders (PSA decline >=50%).

206 patients with advanced heart failure (termed responders [R]) following left ventricular assist device

207 (eight administrations per 1,000 ICU days); responder rate was 77%.

208 mary efficacy endpoint was clinical outcome (responder rate) on day 14.RESULTSClinical responder rate

209 ition of response, strategies to enhance the responder rate, the duration of treatment and its regime

210 dose and any post-baseline seizure data) and responder rates (>=50% reduction) analysed in the mainte

211 The primary endpoint was the comparison of responder rates between the two arms assessed as percent

212 Responder rates during the maintenance phase were 25% (2

213 e (responder rate) on day 14.RESULTSClinical responder rates on day 14 were 70.4% and 60.0% in the ex

214 ive power to distinguish responders from non-responders (receiver operating curve area under the curv

215 enes in both TNBC and NTNBC, but the inducer-responder relationships are different in the two cancer

216 30% or greater decline in MRI-PDFF (MRI-PDFF responders) relative to baseline was 19% versus 50%, res

217 hair may therefore be challenging for first responders, requiring careful management of exposed pers

218 At 6- and 12-month follow-up 42% and 44% of responders, respectively, had persistent respiratory mor

219 However, ACT responders retained a pool of CD39(-) stem-like neoantig

220 m healthy high and low influenza vaccination responders revealed that our signatures reflect the exte

221 According to 40.3% of responders, scientific societies do not provide enough o

222 fered to these patients, clinically complete responders should be accurately identified.

223 Under treatment, tumors in responders showed a mean reduction in size (-9.7%) and m

224 Symptom responders showed an increase in NAc-dorsal anterior cin

225 BF) in bilateral anterior hippocampus, while responders showed CBF increases in right middle and left

226 d surrounding tissue in nonresponders, while responders showed increased GMV in right anterior hippoc

227 0.0006; FDR = 0.004) only in responders, and responders showed significantly more decreased TNF-alpha

228 Furthermore, spatial analysis of two extreme responders shows differential clustering of exhausted CD

229 Conclusion: We have established a GSi-responder signature with evidence across several patient

230 CCA and led to the development of a 225-gene responder signature.

231 Independent baseline predictors of clinical responder status were lower serum creatinine and KCCQ-OS

232 L4 by Week 16 represented biomarkers for the responder subgroup, shedding insights into therapeutic m

233 lack of validated imaging response criteria, responder subgroups with potential survival benefit have

234 e similar to the control subjects, while non-responders tend to remain more similar to their pre-trea

235 cell percentage was significantly higher in responders than in non-responders, while the median Lox-

236 MDSC ratio (NMR) was significantly higher in responders than in non-responders.

237 ome, with significantly longer OS and PFS in responders than in nonresponders according to all assess

238 3-one, or ALT, were observed in histological responders than in nonresponders.

239 The proportions of early endpoint responders that ultimately failed and early endpoint non

240 hat ultimately failed and early endpoint non-responders that ultimately succeeded were similar (6.0%

241 Among 45 responders, the median duration of response was 8.0 mont

242 Dispatching citizen responders through a smartphone application (app) holds

243 membrane is well-positioned to be the first responder to stress.

244 c GMP-AMP (cGAMP) synthase (cGAS) is a major responder to the pathogenic DNA of viruses and bacteria.

245 n correct identification of the patient as a responder to therapy, which was subsequently confirmed v

246 ameters appear to be helpful for identifying responders to adjuvant TMZ early after treatment initiat

247 umor and converts the nonresponder mice into responders to anti-CD47 immunotherapy in a stimulator of

248 the severity of NS phenotypes and potential responders to anti-VEGF therapy.

249 ion cohorts and, in day 28 samples, reported responders to CLL therapy with high accuracy.

250 It can be applied readily by first responders to distinguish methanol from ethanol poisonin

251 1) and its close homologue, PARP2, are early responders to DNA damage in human cells(1,2).

252 s after stratification in responders and non-responders to endoscopic therapy showed that non-respond

253 Metabolic responders to ICI or TT on (18)F-FET PET had a significa

254 Responders to intravenous lidocaine also had significant

255 the irritable (IR) nociceptor phenotype were responders to intravenous lidocaine treatment compared w

256 ral nervous system macrophages and the first responders to neural injury.

257 ll established that diatoms are common first responders to nutrient influxes in aquatic ecosystems, l

258 Symptom responders to sertraline were distinguished by a decreas

259 Stroke Score was assessed and used to define responders to therapy (improvement of >= 4 points on NIH

260 sual recovery helps identify causes for poor responders to treatment in patients with RVO.

261 nto potential biomarkers for identifying low responders to vaccination.

262 eled perfusion MRI may assist in identifying responders to vascular endothelial growth factor recepto

263 r patient (3-month nonresponders and 6-month responders) to aflibercept, ranibizumab and bevacizumab,

264 LSL-tTA knockin and activation of tTA-driven responder transgenes was tested using four transgenic li

265 roscopic residues in R0-specimens of partial responders (tumor regression grade 2-3: N = 90) were fou

266 d categorical outcome (responders versus non-responders) using measurements on the Alda scale.

267 y continuous scores and categorical outcome (responders versus non-responders) using measurements on

268 erentially expressed genes in the tumours of responders versus non-responders.

269 re used to distinguish between good and poor responders (visual Deauville score 1-3 vs. 4-5; DeltaSUV

270 Responders' W15 total FACT-G score had improved (P = .02

271 The geographic distribution of responders was as follows: Africa-Middle East 3.0%, Asia

272 ed from SCI rats showing TTA-P2-induced CPP (responders) was ~6 fold greater than the interspike T-ty

273 Among 24,861 (40.8%) responders, we invited a random sample of 3,200 individu

274 Responders were adults aged 18 to 64 years reporting a p

275 Citizen responders were alerted in 819 suspected OHCAs, of which

276 Genes at integration sites enriched in responders were commonly found in cell-signaling and chr

277 index responders and mean arterial pressure-responders were defined as CI >=10% and mean arterial pr

278 Super-responders were defined as those alive without HF hospit

279 Responders were defined as those alive without HF hospit

280 Responders were further sub-classified by rapidity of re

281 iptome variations between responders and non-responders were identified using the genes significant (

282 No statistically significant differences in responders were observed between SUNCT and SUNA.

283 The sub-optimal responders were pre-defined based on different cut-offs

284 Responders were randomized 1:1 to continue with nabilone

285 Proportions of treatment responders were similar in both groups (70% vs 74.9%; p=

286 ith <20% IOP reduction after 8 weeks, while "responders" were those with >=20% IOP reduction.

287 ma patients (N = 45:34 responders and 11 non-responders) were analysed over the course of omalizumab

288 we distinguish between partial and complete responders, where parts of the vascular system are occlu

289 ishing progressively in complete and partial responders, whereas it remained elevated in nonresponder

290 rved in the CA3 neurons derived from lithium responders while increasing sodium currents and reducing

291 gnificantly higher in responders than in non-responders, while the median Lox-1+ PMN-MDSC percentage

292 nce System data were used to identify survey responders who were asked about the presence of dilated

293 tome gene expression improved ~85% to 95% in responders whose psoriasis area severity index improved

294 ar sensitivity for identifying treatment non-responders with 100% specificity (K(i)(cer): ~50%, SUVRc

295 Of the 24 eyes studied, 79% were anatomical responders with 38% super responders, 17% early responde

296 rating multi-omics identified 64% of the non-responders with 80% confidence.

297 , we simultaneously compared CDDP-incomplete responders with CDDP-complete responders of CC patients

298 y phosphorylated peptides when comparing low responders with high responders.

299 herapies for antidepressant partial- and non-responders with major depressive disorder (MDD), a syste

300 croscopic residue was outside the GTV and in responders with only nodal disease.